|
Department of Defense
High Operational Temperature Sensors
DARPA is accepting applications to develop high-bandwidth, high-dynamic-range analog sensor microelectronics technologies that operate at high-temperature. The program will demonstrate a pressure sensor module consisting of integrated transducer and signal-conditioning microelectronics.
There are three key issues that applicants should seek to address:
- Achieving both long lifetime and large bandwidth transistors at high temperature;
- Achieving a high-sensitivity transducer at high temperature; and
- Integrating a high operating temperature sensor without degrading performance.
Awards:
Multiple awards are anticipated.
Eligibility:
Unrestricted.
Deadline:
08/15/2023
Awards ID(s):
HR001123S0036
Links:
https://go.azcommerce.com/e/629661/-opportunity-html-oppId-348156/5458ks/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Melanoma Research
The Department of Defense is accepting applications for melanoma research. There are three broad categories of focus areas. Applicants must address at least one subtopic under one of the following focus areas:
- Prevention
- Rare melanomas
- Survivorship
There are five opportunities available:
- Idea Award: This award seeks to generate novel research avenues for investigation; therefore, novelty and innovation should be key aspects of the proposed research. Research must introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other creative qualities. Fifteen awards are expected. The total funding pool is $12 million. Preproposal is due July 10. Application is due September 22.
- Melanoma Academy Scholar Award: This award seeks to develop a network of successful, highly productive melanoma researchers in a collaborative research and career development environment. It will enable awardees to pursue a melanoma project that may be basic, translational, and/or clinical research. Three awards are expected. The total funding pool is $2.64 million. Letter of intent is due August 31. Application is due September 22.
- Mid-Career Accelerator Award: This award seeks to support independent, mid-career investigators conducting impactful research on melanoma. Three awards are expected. The total funding pool is $3.48 million. Letter of intent is due August 31. Application is due September 22.
- Team Science Award: This award seeks to bring together investigators from divergent disciplines to achieve innovations and advancements in melanoma research and/or patient care. While basic research is allowed, all applicants are expected to articulate the short- and long-term impacts of the research for the benefit of the melanoma patient community. Six awards are expected. The total funding pool is $12 million. Letter of intent is due August 31. Application is due September 22.
- Focused Program Award – Rare Melanomas: This award seeks to support a multidisciplinary research program of two to three distinct but complementary projects addressing an overarching question relevant to rare melanomas. Applications may propose projects across the entire research spectrum and must address a critical unmet need relevant to rare melanomas. Two awards are expected. The total funding pool is $6.4 million. Letter of intent is due August 31. Application is due September 22.
Eligibility:
Unrestricted.
Awards ID(s):
HT9425-23-MRP-IA, HT9425-23-MRP-MASA, HT9425-23-MRP-MCAA, HT9425-23-MRP-TSA, HT9425-23-MRP-FPA-RM
Links:
https://go.azcommerce.com/e/629661/funding-mrp/5458kw/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Department of Health and Human Services
Advancing Psychedelics Research for Treating Addiction
The National Institute on Drug Abuse (NIAD) seeks to support research to improve our understanding of psychedelic drug mechanisms in the context of substance use disorders (SUDs).
There are three opportunities available:
- Applicants that are interested in conducting mechanistic studies designed to understand a behavior or biological process, the pathophysiology of a disease, or the mechanism of action of an intervention should use the link ending in RFA-DA-24-024.html. Up to four awards are expected. For the R61 planning phase, the combined budget for direct costs for up to two years may not exceed $700,000. For the R33 phase, budgets may not exceed $500,000 per year.
- NIAD will support the design and synthesis of chemical probes to provide mechanistic insights on biological targets modulated by psychedelics, and on common targets/pathways in the context of SUD through the R01 Research Project Grant RFA-DA-24-028. Up to four awards are expected and direct costs may not exceed $350,000 per year per award.
- Applicants proposing Basic Experimental Studies Involving Humans should use the link ending in RFA-DA-24-029.html.
All applicants must submit a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.
Eligibility:
Unrestricted.
Deadline:
11/02/2023
Awards ID(s):
RFA-DA-24-024, RFA-DA-24-028, RFA-DA-24-029
Links:
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-DA-24-024-html/5458kz/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0,
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-DA-24-028-html/5458l3/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0,
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-DA-24-029-html/5458l6/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Alcohol Treatment and Recovery Research
The National Institute on Alcohol Abuse and Alcoholism is accepting applications focusing on alcohol treatment and recovery research. Acceptable topics include medications development, precision medicine, behavioral therapies and mechanisms of behavioral change, recovery, translational research, and innovative methods and technologies for treatment and recovery.
There are two opportunities available:
- Applicants seeking support for a discrete, specified, circumscribed project should use the link ending in PAR-23-187.html. Awards may be up to $500,000 in direct costs.
- Those applying for support for the initial development of a clinical trial or research project, the development of tools for data management and oversight of the research, and/or the development of a trial design or experimental research designs and other essential elements of the study or project should apply to the R34 grant PAR-23-188. Direct costs are limited to $450,000, with no more than $225,000 in any single year.
Eligibility:
Unrestricted.
Deadline:
07/18/2023
Awards ID(s):
PAR-23-187, PAR-23-188
Links:
https://go.azcommerce.com/e/629661/guide-pa-files-PAR-23-187-html/5458l9/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0,
https://go.azcommerce.com/e/629661/guide-pa-files-PAR-23-188-html/5458ld/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets
The National Institute of Allergy and Infectious Diseases seeks to support mechanistic studies of the early stage of Mycobacterium tuberculosis (Mtb) infection, with and without HIV, to identify interventional targets for vaccine and host-directed therapies. Primary focus should be on mechanisms of Mtb-induced immune evasion/disruption of immunity-related cell functions and interactions among myeloid, lymphoid, and non-immune cells within the airway and lung tissue that determine disease progression vs. cessation.
Awards:
3-4 awards are expected. The total funding pool is $2 million.
Eligibility:
Unrestricted.
Deadline:
10/11/2023
Awards ID(s):
RFA-AI-23-029
Links:
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-AI-23-029-html/5458lh/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Assessment of TBI-related ADRD Pathology Related to Cognitive Impairment and Dementia Outcomes
The National Institutes of Health is accepting applications to characterize Alzheimer's disease-related dementias (ADRD) relevant pathology related to cognitive impairment and dementia outcomes in post-mortem brains from persons with a history of traumatic brain injury (TBI). Investigations should elucidate the contribution of key individual and injury characteristics to evaluate associations between neuropathological burden and antemortem clinicopathologic symptoms and outline the prevalence of TBI-related ADRD diagnoses, and CTE pathology in the specimen collected from participating brain banks.
Awards:
2 awards are expected. Direct costs may not exceed $1.3 million per year.
Eligibility:
Unrestricted domestically.
Deadline:
07/28/2023
Awards ID(s):
RFA-NS-24-003
Links:
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-NS-24-003-html/5458ll/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Bioinformatics Resource Centers for Infectious Diseases
The National Institute of Allergy and Infectious Diseases is accepting applications for the Bioinformatics Resource Center (BRC) Program. The goals are to:
- create and manage integrated knowledgebases to accelerate basic and applied human infectious diseases research,
- develop advanced innovative bioinformatics technologies for software and tools,
- offer state-of-the-art bioinformatics expertise for investigators, and
- respond with cutting-edge bioinformatics in response to emerging needs, outbreaks, and public health emergencies.
Applications MUST address at least one ENTIRE set of the following two biological domains:
- viral families; bacterial and archaea; AND metagenomics/microbiome/viromes relevant to infectious diseases
- eukaryotic and metazoan pathogens; vectors for human pathogens; AND hosts-pathogen interactions relevant to biomedical research
Applicants MUST ALSO address all four Key Elements regardless of which Biological Domain(s) is (or are) chosen for the proposed project:
- Key Element 1: Infectious disease knowledgebases
- Key Element 2: Innovative bioinformatics technologies
- Key Element 3: State-of-the-art bioinformatics expertise, outreach, and training
- Key Element 4: Cutting-edge informatics support to rapidly respond to emerging needs, outbreaks, and public health emergencies
Awards:
1-2 awards are expected. The total funding pool is $9 million.
Eligibility:
Unrestricted.
Deadline:
08/25/2023
Awards ID(s):
RFA-AI-23-032
Links:
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-AI-23-032-html/5458lp/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Characterize the Impact of Toxicants on Brain Aging and Alzheimer's Disease and AD-Related Dementias
The National Institute on Aging is accepting applications that propose to use mouse models to evaluate the molecular, pathologic, and functional consequences of major toxicants known to be associated with elevated Alzheimer's Disease (AD) and AD-related dementias (ADRD) risk by conducting cross-sectional/longitudinal multi-modal phenotyping. The central goal is to examine the consequences of early and mid-life exposure on late life brain health.
Awards:
2 awards are expected. The total funding pool is $4 million.
Eligibility:
Unrestricted.
Deadline:
10/23/2023
Awards ID(s):
RFA-AG-24-023
Links:
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-AG-24-023-html/5458ls/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience
The National Institute of Neurological Disorders and Stroke seeks to support interdisciplinary research teams to achieve transformative goals that could not be met by individual or parallel efforts. Applicants should have a single, focused goal, require team-based integration of distinct disciplines and/or viewpoints, and deliver a transformative outcome within 5 years.
Awards:
4-6 awards are expected. The total funding pool is $10 million.
Eligibility:
Unrestricted domestically.
Deadline:
10/20/2023
Awards ID(s):
RFA-NS-23-027
Links:
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-NS-23-027-html/5458lw/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias
The National Institutes of Health seeks to support early development of novel small molecule, or biologic therapeutics to targets that are novel but validated for ADRDs. The R61 phase supports progression through the following research stages: Stage 1) development of in vitro and/or ex vivo assays that can support therapeutic screening efforts, Stage 2) screening efforts to identify and characterize potential therapeutic agents, and Stage 3) therapeutic optimization, pharmacodynamic and pharmacokinetic studies. The R33 phase Stage 4 supports in vivo efficacy studies in an animal model of disease. Applicants must include milestones for each stage of research as well as milestones for the R61/R33 transition.
Projects must have the following characteristics:
- Novelty - Projects should aim to develop or “repurpose” novel small molecule or biologic therapeutics;
- Biological rationale and preliminary data; and
- Relevance for therapy development.
Awards:
Up to 5 awards are expected. The total funding pool is $3.75 million.
Eligibility:
Unrestricted domestically.
Deadline:
09/08/2023
Awards ID(s):
RFA-NS-24-010
Links:
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-NS-24-010-html/5458lz/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes and Potential Risk and Protective Factors
The National Institute of Diabetes and Digestive and Kidney Diseases is accepting applications for cooperative agreements to better understand the neurocognitive impact of new onset type 1 diabetes (T1D) in pre-pubertal children. The goals are to:
- better understand the impact of T1D on the developing brain;
- identify and evaluate potential risk and protective factors associated with T1D-related neurocognitive impact; and
- assess potential associations between use of newer and emerging diabetes management technologies and neurocognitive functioning among children with T1D.
There are two opportunities available:
- Biostatistics Research Centers that would like to participate in a clinical consortium to oversee the development and coordination of a core protocol to be adopted by each Clinical Center can find more information through the link ending in RFA-DK-23-009.html. One award is expected.
- Clinical Centers interested in establishing a diverse cohort of pre-pubertal children newly diagnosed with T1D and will longitudinally evaluate disease-related perturbations in neurocognitive function, as well as identify potential clinical, developmental, and/or environmental factors associated with neurocognitive function in T1D should apply for the award ID RFA-DK-23-010. Up to ten awards are expected.
Awards:
The total funding pool is $5.3 million.
Eligibility:
Unrestricted domestically.
Deadline:
10/26/2023
Awards ID(s):
RFA-DK-23-009, RFA-DK-23-010
Links:
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-DK-23-009-html/5458m3/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0,
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-DK-23-010-html/5458m6/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Quantifying the Impact of Environmental Toxicants on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Risk
The National Institute on Aging is accepting proposals for research focused on major toxicants observed to be associated with elevated Alzheimer's Disease (AD) and AD-related dementias (ADRD) risk, and health disparities in AD/ADRD-related pathologic and clinical outcomes. This goals of this opportunity are:
- Enrich existing longitudinal cohorts with measures of exposures to individual toxicants or combinations of toxicants and/or multi-omics molecular profiling that reflects the body's response to exposure(s);
- Support the development of multi-disciplinary teams needed for the rigorous measurement and assessment of environmental exposures at the population level; and
- Create an environmental epidemiology consortium to facilitate rapid and broad data sharing, harmonization, and integration of complex exposure data across multiple studies to enhance the opportunity for data pooling and data integration for various meta-analyses and/or comparative analyses.
Applicants must justify the following:
- gaps in knowledge that will be addressed by the cohort;
- selection of the study population and/or the inclusion of minority health or health disparate populations;
- collection and use of biological specimens for analysis; and
- environmental toxicants to be assessed and the reliability and validity of methods of assessment and outcome measures.
Awards:
4-5 awards are expected. The total funding pool is $11 million.
Eligibility:
Unrestricted.
Deadline:
10/23/2023
Awards ID(s):
RFA-AG-24-022
Links:
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-AG-24-022-html/5458m9/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Significance of Clonal Hematopoiesis in Aging Humans
The National Institute on Aging is accepting applications that utilize existing biospecimens and datasets which will increase our understanding of the clinical significance of clonal hematopoiesis (CH) mutations, their causality, directionality, relationships with different human aging phenotypes, and underlying biological mechanisms. Specifically, this opportunity seeks to support studies using sequencing-based analyses of biospecimens from epidemiological cohorts with extensive physiologic, genetic, and omics data to assess the clinical significance of somatic mutations for a variety of age-related outcomes. New data and specimen collection to supplement existing datasets is allowed when essential. Studies should consider effects
of CH mutations and the molecular mechanisms of CH in aging.
Awards:
4 awards are expected. Application budgets may seek up to $1 million in direct costs.
Eligibility:
Unrestricted.
Deadline:
10/23/2023
Awards ID(s):
RFA-AG-24-038
Links:
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-AG-24-038-html/5458md/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Specialized Centers for Research on Health Disparities in Uterine Leiomyoma
The National Institute of Child Health and Human Development seeks to establish new Specialized Centers for Research on Health Disparities in Uterine Leiomyoma. These centers will provide a platform to support research programs spanning basic, clinical, translational, behavioral, and social sciences research to address health disparities in uterine fibroids. The established centers will aim to improve women's reproductive health and address modifiable aspects of the racial and associated health disparities in uterine fibroids through greater understanding of biologic, behavioral, and environmental differences in risk, disease progression, and treatment. Each center's three or more projects may be entirely behavioral and/or social
research projects; a mix of basic and/or clinical projects; or a mix of social and/or behavioral, basic, and/or clinical projects.
The scope includes projects that will:
- enhance our understanding of the etiology, pathophysiology, and progression of fibroids and how these differ in populations that experience health disparities; and/or
- enable the development of more effective strategies for the diagnosis, management, and prevention of this disorder that directly impact demonstrated disparities.
Awards:
2 awards are expected. Direct costs may not exceed $1 million per year per award.
Eligibility:
Unrestricted domestically.
Deadline:
08/07/2023
Awards ID(s):
RFA-HD-24-005
Links:
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-HD-24-005-html/5458mh/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Understanding Gene-Environment Interactions in Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias
The National Institute on Aging is accepting applications for interdisciplinary research projects that utilize disease relevant human cell-based in vitro and ex vivo models to characterize the effects of gene-environment (GxE) interactions on gene regulation and cellular functions, and to elucidate toxicant mediated molecular and cellular mechanisms in brain aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD). Collaborations between neuroscience researchers and environmental health scientists are strongly encouraged.
Awards:
5-6 awards are expected. The total funding pool is $3.5 million.
Eligibility:
Unrestricted.
Deadline:
10/23/2023
Awards ID(s):
RFA-AG-24-021
Links:
https://go.azcommerce.com/e/629661/e-rfa-files-RFA-AG-24-021-html/5458ml/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
Environmental Protection Agency
Evaluation of Antimicrobial Resistance in Wastewater and Sewage Sludge Treatment and Its Impact on the Environment
The EPA is accepting applications for research in the occurrence, fate and transport, and persistence of antimicrobial resistant organisms and genes found in municipal wastewater effluent and biosolids.
There are two research areas:
- Understanding the selection and removal of antimicrobial resistant genes and bacteria throughout wastewater and biosolids treatment trains.
- Understanding the environmental burden and public health impact of antimicrobial resistant genes and bacteria from different municipal wastewater sources on downstream applications and from biosolids use on the environment.
Awards:
4 awards are expected of up to $2.375 million in total costs each.
Eligibility:
Unrestricted except for government entities.
Deadline:
08/16/2023
Awards ID(s):
EPA-G2023-ORD-F1
Links:
https://go.azcommerce.com/e/629661/-opportunity-html-oppId-348230/5458mp/895190261?h=7QR-IeLBpRwRrbfBMIZWfbOQ7xTR4RnLgxPhfAltgp0
|
